Heart Failure and Impaired Kidney Function - Pearland TX (Metro Houston)

Summary:

A Phase III, Randomized, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function

1. Participant must be ≥ 18 years old

2.  Documented diagnosis of symptomatic HF (NYHA functional Class II to IV), present before the last event.

3. Having had a recent HF event, defined as either:

a.      A hospitalization primarily for a HF indication including signs and symptoms of congestions and use of parenteral medications for HF during admission within 6 months prior to randomization

b.      An urgent HF visit with outpatient parenteral medications for HF within 6 months prior to randomization

c.    Currently hospitalized due to worsening of chronic HF, but with none of the following within the last 24 hours of randomization

                                                    i.          Invasive or non-invasive ventilation

                                                   ii.          IV vasopressor, IV vasodilator use including nitrates or IV inotropes

                                                  iii.          Increase in dose of IV diuretics

Qualified Participants May Receive:

$200 at Visit 1
$200 at Visit 2

$100 for all other study visits